26Oct 2023
Advances in SGLT-2 Inhibition for Kidney Health – UK Kidney Association 2023 Update

Advances in SGLT-2 Inhibition for Kidney Health – UK Kidney Association 2023 Update

Recent large trials, EMPA-KIDNEY and DELIVER, have shown that SGLT-2 inhibitors offer clinical benefits for kidneys and cardiovascular health. This prompted an update to the UK Kidney Association Clinical Practice Guideline. The update covers the use of these inhibitors in various conditions, such as type 1 diabetes, kidney transplants, and heart failure hospital admissions. It also outlines recommendations for future research and implementation. The guidelines include a simplified summary for non-medical individuals, making the information accessible to a broader audience.

  • #nephrology

Like

Save

Share